Lipid–Polymer Nanoparticles Encapsulating Doxorubicin and 2′-Deoxy-5-azacytidine Enhance the Sensitivity of Cancer Cells to Chemical Therapeutics

Xianwei Su; ZHAOHUI WANG; Lili Li; Mingbin Zheng; Cuifang Zheng; Ping Gong; Pengfei Zhao; Yifan Ma; Qian Tao; Lintao Cai

doi:10.1021/mp300675c

journal article Apr 25, 2013

Lipid–Polymer Nanoparticles Encapsulating Doxorubicin and 2′-Deoxy-5-azacytidine Enhance the Sensitivity of Cancer Cells to Chemical Therapeutics

Xianwei Su

ZHAOHUI WANG

Lili Li

Mingbin Zheng Cuifang Zheng Ping Gong

Molecular Pharmaceutics Vol. 10 No. 5 pp. 1901-1909 · American Chemical Society (ACS)

View at Publisher Save 10.1021/mp300675c

Topics

No keywords indexed for this article. Browse by subject →

References

36

[1]

Singal P. K. N. Engl. J. Med. (1998) 10.1056/nejm199809243391307

[2]

Davis M. E. Nat. Rev. Drug Discovery (2008) 10.1038/nrd2614

[3]

Brannon-Peppas L. Adv. Drug Delivery Rev. (2004) 10.1016/j.addr.2004.02.014

[4]

Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications

Jinjun Shi, Alexander R. Votruba, Omid C. Farokhzad et al.

Nano Letters 2010 10.1021/nl102184c

[5]

Maeda H. Adv. Enzyme Regul. (2001) 10.1016/s0065-2571(00)00013-3

[6]

Matsumura Y. Cancer Res. (1986)

[7]

Chang A. Lung Cancer (2011) 10.1016/j.lungcan.2010.08.022

[8]

Sengupta S. Nature (2005) 10.1038/nature03794

[9]

Coley H. M. Cancer Treat. Rev. (2008) 10.1016/j.ctrv.2008.01.007

[10]

Lai D. Biosci. Rep. (2012) 10.1042/bsr20110125

[11]

Fojo T. Oncogene (2003) 10.1038/sj.onc.1206951

[12]

Lage H. Curr. Drug Targets (2006) 10.2174/138945006777709566

[13]

Perez J. Anticancer Res. (2011)

[14]

Abbasi M. Pharm. Res. (2011) 10.1007/s11095-011-0480-z

[15]

Xia Z. Oncol. Rep. (2008)

[16]

Chen A. M. Small (2009) 10.1002/smll.200900621

[17]

Baylin S. B. Nat. Rev. Cancer (2006) 10.1038/nrc1799

[18]

Jones P. A. Cell (2007) 10.1016/j.cell.2007.01.029

[19]

Reid G. K. Curr. Opin. Mol. Ther. (2002)

[20]

Kuendgen A. Ann. Hematol. (2008) 10.1007/s00277-008-0477-9

[21]

Mund C. BioEssays (2010) 10.1002/bies.201000061

[22]

Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines

Christian N. Arnold, Ajay Goel, C. Richard Boland

International Journal of Cancer 2003 10.1002/ijc.11176

[23]

Jin H. Proc. Natl. Acad. Sci. U.S.A. (2007) 10.1073/pnas.0700153104

[24]

Murray P. G. Oncogene (2004) 10.1038/sj.onc.1207313

[25]

Kaminskyy V. O. Carcinogenesis (2011) 10.1093/carcin/bgr135

[26]

Plumb J. A. Cancer Res. (2000)

[27]

Xu J. Cancer Res. (2007) 10.1158/0008-5472.can-06-2310

[28]

Shang D. Cancer Lett. (2009) 10.1016/j.canlet.2008.12.034

[29]

George R. E. Pediatr. Blood Cancer (2010) 10.1002/pbc.22607

[30]

Zheng C. Biomaterials (2012) 10.1016/j.biomaterials.2012.04.044

[31]

Lin K.-T. J. Pharm. Sci. (1981) 10.1002/jps.2600701112

[32]

Wei G. Biomed. Chromatogr. (2008) 10.1002/bmc.1054

[33]

Qiu G. H. J. Hepatol. (2008) 10.1016/j.jhep.2007.11.015

[34]

Seng T. J. Oncogene (2006) 10.1038/sj.onc.1209839

[35]

Zhang Q. Cancer Lett. (2007) 10.1016/j.canlet.2006.08.019

[36]

Li B. Int. J. Nanomed. (2012)

Cited By

55

Lipid–Polymer Hybrid Nanosystems: A Rational Fusion for Advanced Therapeutic Delivery

Shweta Jain, Mudit Kumar · 2023

Journal of Functional Biomaterials

Metrics

55

Citations

36

References

Details

Published: Apr 25, 2013
Vol/Issue: 10(5)
Pages: 1901-1909

Authors

X

Xianwei Su

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

Z

ZHAOHUI WANG

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

L

Lili Li

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China; Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong and CUHK Shenzhen Research Institute, Hong Kong

M

Mingbin Zheng

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China; Department of Chemistry, Guangdong Medical College, Dongguan 523808, P. R. China

C

Cuifang Zheng

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

P

Ping Gong

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

P

Pengfei Zhao

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

Y

Yifan Ma

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

Q

Qian Tao

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China; Cancer Epigenetics Laboratory, Department of Clinical Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong and CUHK Shenzhen Research Institute, Hong Kong

L

Lintao Cai

Guangdong Key Laboratory of Nanomedicine, Shenzhen Key Laboratory of Cancer Nanotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, P. R. China

Cite This Article

Xianwei Su, ZHAOHUI WANG, Lili Li, et al. (2013). Lipid–Polymer Nanoparticles Encapsulating Doxorubicin and 2′-Deoxy-5-azacytidine Enhance the Sensitivity of Cancer Cells to Chemical Therapeutics. Molecular Pharmaceutics, 10(5), 1901-1909. https://doi.org/10.1021/mp300675c

Lipid–Polymer Nanoparticles Encapsulating Doxorubicin and 2′-Deoxy-5-azacytidine Enhance the Sensitivity of Cancer Cells to Chemical Therapeutics

You May Also Like